SAT660 Predictors Of Achieving Body Weight Reduction ≥20% With Tirzepatide In People With Overweight Or Obesity In SURMOUNT-1
Authors: Srinath Reshmi , Pedersen Sue , Neff Lisa , Cao Dachuang , Kao Christi Y , Stefanski Adam , Ahmad Nadia , Eun Lee Clare Jung 
Published: October 2023

Disclosure: R. Srinath: Grant Recipient; Self; Dexcom. S. Pedersen: Other; Self; AstraZeneca, Bausch, Eli Lilly & Company, Novo Nordisk, Jansen Pharmaceuticals, Boehringer Ingelheim, Sanofi, Merck, Abbott Laboratories, HLS, Bayer, Inc., Pfizer, Inc., Dexcom. L. Neff: Employee; Self; Eli Lilly & Company. D. Cao: Employee; Self; Eli Lilly & Company. C.Y. Kao: Employee; Self; Eli Lilly & Company. A. Stefanski: Employee; Self; Eli Lilly & Company. N. Ahmad: Employee; Self; Eli Lilly & Company. C.J. Lee: Employee; Self; Eli Lilly & Company.

Background: Obesity is a chronic progressive disease affecting a growing number of adults and associated with many related complications. Next-generation anti-obesity medications (AOM) help achieve substantial body weight (BW) reduction needed to delay or prevent obesity-related complications. BW reduction of 20% or greater, once considered possible only with bariatric surgery, is now an achievable goal with next-generation AOMs. Tirzepatide, a GIP/GLP-1 receptor agonist approved for T2D and in development for chronic weight management, resulted in mean BW reduction of 15 - 21% in the Phase 3 SURMOUNT-1 double-blind, randomized, controlled trial. In this analysis we aimed to investigate predictors of achieving BW reduction ≥20 % with tirzepatide treatment in this trial. Methods: Adults with overweight or obesity who were randomized to receive once-weekly, subcutaneous (SC) tirzepatide (5 mg, 10 mg, or 15 mg) for 72 weeks and adherent to tirzepatide (≥75% doses received) were included in this analysis. Descriptive statistics were calculated for baseline values. Univariate logistic regression was performed on baseline demographics and laboratory values. Variables identified through a stepwise logistic regression were further analysed using a multivariate logistic regression model. Results: Among 1834 participants included in this analysis, 951 (52%) participants achieved 20% or greater BW reduction at week 72. Baseline factors associated with significantly higher odds of achieving BW reduction of ≥20% were female sex (OR [95% CI], p-value) (2.38 [1.90, 2.98], &lt;0.001), lower baseline serum alanine aminotransferase (ALT) levels (1.17 [1.05, 1.30], 0.005), lower baseline HbA1c levels (1.62 [1.24, 2.10), &lt;0.001), and no diagnosed hypertension (1.35 [1.09, 1.68], 0.005) based on multivariate analysis. Baseline factors not associated with higher odds of achieving BW reduction ≥20% were age, race, BW, years of education, fasting insulin, and systolic blood pressure. Conclusions: Approximately half of participants with obesity or overweight, without diabetes, treated with tirzepatide achieved BW reduction of 20% or greater in the SURMOUNT-1 study. Factors associated with a higher likelihood of achieving BW reduction of 20% or greater were female sex, lower ALT, lower HbA1c and no diagnosed hypertension at baseline. These findings may help guide obesity treatment goals and expectations with tirzepatide treatment, which is under investigation for chronic weight management.

Presentation: Saturday, June 17, 2023